226 related articles for article (PubMed ID: 7802690)
1. Evaluation of estrogen receptor, antiestrogen binding sites and calmodulin for antiestrogen resistance of two clones derived from the MCF-7 breast cancer cell line.
Borras M; Jin L; Bouhoute A; Legros N; Leclercq G
Biochem Pharmacol; 1994 Nov; 48(11):2015-24. PubMed ID: 7802690
[TBL] [Abstract][Full Text] [Related]
2. Role of estrogen receptors and antiestrogen binding sites in an early effect of antiestrogens, the inhibition of cholesterol biosynthesis.
Cypriani B; Tabacik C; Descomps B; Crastes de Paulet A
J Steroid Biochem; 1988 Nov; 31(5):763-71. PubMed ID: 3199816
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical and genetic evidence for specific antiestrogen binding sites.
Faye JC; Jozan S; Redeuilh G; Baulieu EE; Bayard F
Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3158-62. PubMed ID: 6574477
[TBL] [Abstract][Full Text] [Related]
4. Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen.
Herman ME; Katzenellenbogen BS
J Steroid Biochem Mol Biol; 1996 Oct; 59(2):121-34. PubMed ID: 9010327
[TBL] [Abstract][Full Text] [Related]
5. Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity.
Pavlik EJ; Nelson K; Srinivasan S; Powell DE; Kenady DE; DePriest PD; Gallion HH; van Nagell JR
Cancer Res; 1992 Aug; 52(15):4106-12. PubMed ID: 1638522
[TBL] [Abstract][Full Text] [Related]
6. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
Miller MA; Lippman ME; Katzenellenbogen BS
Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
[TBL] [Abstract][Full Text] [Related]
7. Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.
Vignon F; Lippman ME; Nawata H; Derocq D; Rochefort H
Cancer Res; 1984 May; 44(5):2084-8. PubMed ID: 6713400
[TBL] [Abstract][Full Text] [Related]
8. Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018.
Bronzert DA; Greene GL; Lippman ME
Endocrinology; 1985 Oct; 117(4):1409-17. PubMed ID: 4029083
[TBL] [Abstract][Full Text] [Related]
9. Compared effects of GnRH analogs and 4-hydroxytamoxifen on growth and steroid receptors in antiestrogen sensitive and resistant MCF-7 breast cancer cell sublines.
Néri C; Berthois Y; Schatz B; Drieu K; Martin PM
Breast Cancer Res Treat; 1990 Feb; 15(2):85-93. PubMed ID: 2138918
[TBL] [Abstract][Full Text] [Related]
10. Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells.
Burke PJ; Kalet BT; Koch TH
J Med Chem; 2004 Dec; 47(26):6509-18. PubMed ID: 15588086
[TBL] [Abstract][Full Text] [Related]
11. ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness.
Thompson EW; Katz D; Shima TB; Wakeling AE; Lippman ME; Dickson RB
Cancer Res; 1989 Dec; 49(24 Pt 1):6929-34. PubMed ID: 2582435
[TBL] [Abstract][Full Text] [Related]
12. Antiestrogenic effects of LY 117018 in MCF-7 cells.
Scholl SM; Huff KK; Lippman ME
Endocrinology; 1983 Aug; 113(2):611-7. PubMed ID: 6872943
[TBL] [Abstract][Full Text] [Related]
13. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
14. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
15. [Effects of estrogen and endocrine therapeutic agents on the estrogen receptor, progesterone receptor and DNA synthesis in MCF-7 human breast cancer cells using the whole cell uptake method].
Kurebayashi J; Horiuchi R; Nakamura T; Iino Y; Ishida T; Takigawa H; Izuo M
Nihon Naibunpi Gakkai Zasshi; 1987 Nov; 63(11):1351-63. PubMed ID: 2965035
[TBL] [Abstract][Full Text] [Related]
16. Modifications of benzylphenoxy ethanamine antiestrogen molecules: influence affinity for antiestrogen binding site (AEBS) and cell cytotoxicity.
Delarue F; Kedjouar B; Mésange F; Bayard F; Faye JC; Poirot M
Biochem Pharmacol; 1999 Mar; 57(6):657-61. PubMed ID: 10037451
[TBL] [Abstract][Full Text] [Related]
17. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
[TBL] [Abstract][Full Text] [Related]
18. The pure antiestrogen ICI 182,780 binds to a high-affinity site distinct from the estrogen receptor.
Parisot JP; Hu XF; Sutherland RL; Wakeling A; Zalcberg JR; DeLuise M
Int J Cancer; 1995 Aug; 62(4):480-4. PubMed ID: 7635575
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of a non-binding form of estrogen receptor in MCF-7 cells under hydroxytamoxifen treatment.
Leclercq G; Legros N; Piccart MJ
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):545-52. PubMed ID: 1562525
[TBL] [Abstract][Full Text] [Related]
20. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F
Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
